Tirzepatide works by activating two hormone receptors at once: GIP and GLP-1 receptors. These are key regulators of insulin secretion, and they’re also found in brain regions that control appetite. This dual action is what sets tirzepatide apart from older medications like semaglutide, which only target one of those receptors. The result is stronger effects on both blood sugar and body weight.
Two Gut Hormones, One Drug
When you eat, your gut naturally releases two hormones called GIP and GLP-1. Both signal your pancreas to produce insulin, helping clear sugar from your bloodstream. Tirzepatide is an engineered peptide that mimics both of these hormones simultaneously.
GLP-1 receptor agonists like semaglutide have been available for years, and they work well. But tirzepatide’s addition of GIP receptor activation appears to amplify the overall effect. In head-to-head trials, tirzepatide improved insulin sensitivity and insulin secretion more than semaglutide did, and it produced greater weight loss despite similar reductions in appetite between the two drugs. Researchers are still working out exactly why GIP agonism adds this extra benefit, since GIP’s effects on weight and appetite haven’t been clearly demonstrated in humans on their own. The combination, though, clearly outperforms GLP-1 alone.
How It Controls Blood Sugar
Tirzepatide lowers blood sugar through two complementary actions in the pancreas. It increases insulin secretion and reduces glucagon release, both in a glucose-dependent manner. That last detail matters: the drug ramps up insulin production when blood sugar is high and dials it back when blood sugar is normal. This glucose-dependent design significantly lowers the risk of hypoglycemia compared to medications that push insulin out regardless of what your blood sugar is doing.
Tirzepatide also slows down how quickly your stomach empties food into your small intestine. Gastric emptying is a major factor in post-meal blood sugar spikes, accounting for roughly a third of the initial glucose rise after eating. By transiently delaying this process, tirzepatide blunts those spikes and reduces the amount of triglycerides and other fats entering your bloodstream after meals. This effect is similar to what GLP-1-only drugs do.
Across six phase 3 clinical trials in people with type 2 diabetes (the SURPASS program), tirzepatide reduced HbA1c by 1.9 to 2.6 percentage points, with weight reductions ranging from about 6 to 12 kilograms depending on the dose and trial.
How It Reduces Appetite and Weight
Beyond what happens in the pancreas and stomach, tirzepatide acts directly on the brain. It binds to GLP-1 receptors in the hindbrain, activating satiety signaling pathways that make you feel full sooner and reduce the drive to eat. This part of the brain remains functional even in people with certain types of hypothalamic damage, which suggests tirzepatide’s appetite effects are robust across different populations.
The GIP receptor side of the drug contributes its own weight-loss effects through a different route. GIP receptors are found in fat tissue and in the central nervous system, where they help regulate energy balance. Research suggests GIP receptor activation may influence the melanocortin pathway in the hypothalamus, a core system the brain uses to match energy intake to energy expenditure.
The weight loss results are substantial. In the SURMOUNT-1 trial of adults with obesity (without diabetes), participants on the highest dose lost an average of 20.9% of their body weight over 72 weeks. That level of weight reduction was essentially unheard of with medications before tirzepatide.
Why It’s a Once-Weekly Injection
Tirzepatide has a half-life of about 5.4 days, meaning it takes that long for half the drug to clear your system. This slow elimination allows it to maintain steady levels in your blood with just one subcutaneous injection per week. With repeated weekly dosing, drug concentrations accumulate to about 1.7 times the single-dose level, reaching a stable therapeutic range.
The starting dose is 2.5 mg once weekly, which is not a maintenance dose. It’s designed to let your body adjust. After four weeks, the dose increases to 5 mg, and from there it can go up by 2.5 mg increments every four weeks or longer. The maximum dose is 15 mg. Maintenance doses for weight management are typically 5 mg, 10 mg, or 15 mg depending on individual response and tolerability.
What It’s Approved For
Tirzepatide is sold under two brand names for two different uses. As Mounjaro, it’s approved for improving blood sugar control in adults with type 2 diabetes. As Zepbound, it was approved in November 2023 for chronic weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as high blood pressure or high cholesterol. Both are meant to be used alongside diet changes and increased physical activity.
Common Side Effects
The most frequent side effects are gastrointestinal, which makes sense given how the drug works on gut hormone receptors and stomach motility. In a meta-analysis of clinical trial data, about 20% of people taking tirzepatide experienced nausea (compared to 10% on placebo or comparator drugs), 16% had diarrhea (versus 9%), and 9% had vomiting (versus 5%). These effects are most common during dose escalation and tend to improve as the body adjusts. The gradual titration schedule, increasing by 2.5 mg every four weeks or more, is specifically designed to minimize these symptoms.
The slower gastric emptying that helps with blood sugar control is also the likely driver of these GI effects. Food sitting in the stomach longer can cause nausea and discomfort, particularly at higher doses or when eating large meals.